Biggest News Aggregation in the World

Sandesh Seth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sandesh Seth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sandesh Seth Today - Breaking & Trending Today

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

Published: March 26, 2024

Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a multi-billion market with six FDA approved...

Source: prnewswire.com

$Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia - Vimarsana News$

Actinium s Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Published: December 12, 2023

NEW YORK - Actinium Pharmaceuticals, Inc. , a leader in the development of targeted radiotherapies, today highlighted four presentations at the 65th Annual American Society of Hematology Annual...

Source: marketscreener.com

Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations

Published: November 6, 2023

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

Source: prnewswire.com

Actinium Appoints Lynn Bodarky as Chief Business Officer

Published: November 3, 2023

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

Source: prnewswire.com

Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy

Published: October 4, 2023

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies,...

Source: prnewswire.com